Application of Quality of Experience in Networked Services: Review, Trend & Perspectives

Full text embargoed until 17.10.2019 (publisher's embargo period, 12 months

Quality of Experience Framework for Cloud Computing (QoC)

Cloud computing provides platform for pay per use services such as software (e.g., database, data processing, application servers, etc.), hardware (e.g., GPUs, CPUs, storage, etc.) and platforms (e.g., Linux, Microsoft Windows and Apple macOS). Previous cloud frameworks use fix policies that do not have the functionality to upgrade services on demand when the user do not receive services according to Service Level Agreement (SLA). Also, there was a lack of functionality to monitor external network and client device resources. This paper presents Quality of experience framework for Cloud computing (QoC) for monitoring the Quality of Experience (QoE) of the end user using video streaming services in the cloud computing environment. The management platform is used for administration purpose in QoC framework that provides facility to easily manage the cloud environment and provide services according to SLA via runtime policy change. The objective QoE/QoS section will automatically monitor the Quality of Service (QoS) data. It will also compare and analyze the subjective QoE submitted by the users and objective QoS data collected by agent based framework for accurate QoE prediction and proper management. The proposed QoC framework has new features of real time network monitoring, client device monitoring and allows changing policy in runtime environment which to our knowledge is currently not provided by existing frameworks

Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic

Introduction Childhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality. Methods Prospective cohort study in 109 institutions in 41 countries. Inclusion criteria: children <18 years who were newly diagnosed with or undergoing active treatment for acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, retinoblastoma, Wilms tumour, glioma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, medulloblastoma and neuroblastoma. Of 2327 cases, 2118 patients were included in the study. The primary outcome measure was all-cause mortality at 30 days, 90 days and 12 months. Results All-cause mortality was 3.4% (n=71/2084) at 30-day follow-up, 5.7% (n=113/1969) at 90-day follow-up and 13.0% (n=206/1581) at 12-month follow-up. The median time from diagnosis to multidisciplinary team (MDT) plan was longest in low-income countries (7 days, IQR 3-11). Multivariable analysis revealed several factors associated with 12-month mortality, including low-income (OR 6.99 (95% CI 2.49 to 19.68); p<0.001), lower middle income (OR 3.32 (95% CI 1.96 to 5.61); p<0.001) and upper middle income (OR 3.49 (95% CI 2.02 to 6.03); p<0.001) country status and chemotherapy (OR 0.55 (95% CI 0.36 to 0.86); p=0.008) and immunotherapy (OR 0.27 (95% CI 0.08 to 0.91); p=0.035) within 30 days from MDT plan. Multivariable analysis revealed laboratory-confirmed SARS-CoV-2 infection (OR 5.33 (95% CI 1.19 to 23.84); p=0.029) was associated with 30-day mortality. Conclusions Children with cancer are more likely to die within 30 days if infected with SARS-CoV-2. However, timely treatment reduced odds of death. This report provides crucial information to balance the benefits of providing anticancer therapy against the risks of SARS-CoV-2 infection in children with cancer